This case involves an individual who held a 15% stake in a publicly traded international business that conducted biomedical and pharmaceutical research. In the interest of acquiring a single, clinically important drug used in the treatment of autoimmune disorders, the individual proposed, negotiated, and established a merger agreement with another company that produced that drug exclusively. However, it was subsequently claimed that the terms of the merger agreement were not met, and that the valuation of the smaller company in the original merger agreement was significantly overestimated.
